Recordati Industria Chimica e Farmaceutica S.p.A.

BIT:REC Rapport sur les actions

Capitalisation boursière : €10.2b

Recordati Industria Chimica e Farmaceutica Gestion

Gestion contrôle des critères 4/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Rob Koremans

Directeur général

€2.5m

Rémunération totale

Pourcentage du salaire du PDG23.6%
Durée du mandat du directeur général2.9yrs
Propriété du PDGn/a
Durée moyenne d'occupation des postes de direction4.2yrs
Durée moyenne du mandat des membres du conseil d'administration5.2yrs

Mises à jour récentes de la gestion

Recent updates

We Like The Quality Of Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings

Nov 18
We Like The Quality Of Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings

Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Due To Pay A Dividend Of €0.60

Nov 14
Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Due To Pay A Dividend Of €0.60

Earnings Beat: Recordati Industria Chimica e Farmaceutica S.p.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Nov 13
Earnings Beat: Recordati Industria Chimica e Farmaceutica S.p.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Not Flying Under The Radar

Oct 31
Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Not Flying Under The Radar

Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Sep 07
Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt

Aug 20
We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt

Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 31% And Analysts Are Revising Their Forecasts

Aug 02
Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 31% And Analysts Are Revising Their Forecasts

Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Business Is Yet to Catch Up With Its Share Price

Aug 01
Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Business Is Yet to Catch Up With Its Share Price

Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

May 26
Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.63

May 10
Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.63

Recordati Industria Chimica e Farmaceutica's (BIT:REC) Dividend Will Be Increased To €0.63

Apr 25
Recordati Industria Chimica e Farmaceutica's (BIT:REC) Dividend Will Be Increased To €0.63

Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Share Price Could Signal Some Risk

Apr 23
Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Share Price Could Signal Some Risk

If EPS Growth Is Important To You, Recordati Industria Chimica e Farmaceutica (BIT:REC) Presents An Opportunity

Apr 08
If EPS Growth Is Important To You, Recordati Industria Chimica e Farmaceutica (BIT:REC) Presents An Opportunity

Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.63

Mar 23
Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.63

Is Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 27
Is Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Expensive For A Reason? A Look At Its Intrinsic Value

We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt

Jan 09
We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt

Risks To Shareholder Returns Are Elevated At These Prices For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Dec 22
Risks To Shareholder Returns Are Elevated At These Prices For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.57

Nov 12
Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.57

Is Recordati Industria Chimica e Farmaceutica (BIT:REC) Using Too Much Debt?

Sep 29
Is Recordati Industria Chimica e Farmaceutica (BIT:REC) Using Too Much Debt?

Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Sep 08
Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly

Jun 23
Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly

Does This Valuation Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Imply Investors Are Overpaying?

Jun 05
Does This Valuation Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Imply Investors Are Overpaying?

Recordati Industria Chimica e Farmaceutica's (BIT:REC) Conservative Accounting Might Explain Soft Earnings

Apr 08
Recordati Industria Chimica e Farmaceutica's (BIT:REC) Conservative Accounting Might Explain Soft Earnings

Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.60

Apr 05
Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.60

Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.60

Mar 19
Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.60

Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly

Mar 06
Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly

A Look At The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Dec 23
A Look At The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?

Dec 05
Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?

Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.55

Nov 11
Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.55

Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Intrinsic Value Is Potentially 42% Above Its Share Price

Sep 01
Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Intrinsic Value Is Potentially 42% Above Its Share Price

These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well

Aug 07
These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well

An Intrinsic Calculation For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Suggests It's 25% Undervalued

Jun 03
An Intrinsic Calculation For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Suggests It's 25% Undervalued

Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year

May 16
Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year

Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year

May 02
Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year

Recordati Industria Chimica e Farmaceutica's (BIT:REC) Shareholders Will Receive A Bigger Dividend Than Last Year

Apr 18
Recordati Industria Chimica e Farmaceutica's (BIT:REC) Shareholders Will Receive A Bigger Dividend Than Last Year

Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.57

Apr 04
Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.57

Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.57

Mar 21
Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.57

These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well

Mar 06
These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well

Calculating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Dec 22
Calculating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Recordati Industria Chimica e Farmaceutica (BIT:REC) Has A Pretty Healthy Balance Sheet

Dec 05
Recordati Industria Chimica e Farmaceutica (BIT:REC) Has A Pretty Healthy Balance Sheet

Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Sep 23
Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?

Sep 05
Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?

A Look At The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Jun 25
A Look At The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly

Jun 07
Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly

Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 8.5% And Analysts Are Revising Their Forecasts

May 10
Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 8.5% And Analysts Are Revising Their Forecasts

Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Shares Could Be 34% Above Their Intrinsic Value Estimate

Mar 11
Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Shares Could Be 34% Above Their Intrinsic Value Estimate

Here's What You Should Know About Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) 2.4% Dividend Yield

Feb 19
Here's What You Should Know About Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) 2.4% Dividend Yield

Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Jan 30
Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Analyse de la rémunération des PDG

Comment la rémunération de Rob Koremans a-t-elle évolué par rapport aux bénéfices de Recordati Industria Chimica e Farmaceutica?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

€423m

Jun 30 2024n/an/a

€387m

Mar 31 2024n/an/a

€389m

Dec 31 2023€2m€590k

€389m

Sep 30 2023n/an/a

€375m

Jun 30 2023n/an/a

€389m

Mar 31 2023n/an/a

€340m

Dec 31 2022€2m€590k

€312m

Sep 30 2022n/an/a

€331m

Jun 30 2022n/an/a

€330m

Mar 31 2022n/an/a

€393m

Dec 31 2021€154kn/a

€386m

Rémunération vs marché: La rémunération totale de Rob ($USD 2.64M ) est dans la moyenne des entreprises de taille similaire sur le marché Italian ($USD 3.23M ).

Rémunération et revenus: La rémunération de Rob a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Rob Koremans (62 yo)

2.9yrs

Titularisation

€2,498,000

Compensation

Dr. Robert Koremans, also known as Rob, M.D. serves as Chief Executive Officer and Director of Recordati Industria Chimica e Farmaceutica S.p.A. since December 1, 2021. Dr. Koremans served as Chief Executi...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Robert Koremans
CEO & Director2.9yrs€2.50mpas de données
Luigi Felice Corte
Group CFO & Executive Director5yrs€1.23mpas de données
Cathrin Petty
Executive Directorno datapas de donnéespas de données
Giampiero Mazza
Executive Director5.8yrspas de donnéespas de données
Giorgio De Palma
Executive Director4.6yrspas de donnéespas de données
Eugenia Litz
VP & Head of Investor Relationsless than a yearpas de donnéespas de données
Bibianne Bon
Group Chief Legal Officer1.6yrspas de donnéespas de données
Laura Conti
Group Communications Directorno datapas de donnéespas de données
Gabriele Finzi
Executive VP of Corporate Development8.2yrspas de donnéespas de données
Alessandra Abate
Group Chief People & Culture Officerless than a yearpas de donnéespas de données
Raffaele Sabia
Chief Medical Officer5.8yrspas de donnéespas de données
Alberto Martinez
Executive Vice President of Specialty & Primary Care Business Unit3.8yrspas de donnéespas de données

4.2yrs

Durée moyenne de l'emploi

55yo

Âge moyen

Gestion expérimentée: L'équipe de direction de REC est considérée comme expérimentée (ancienneté moyenne 4.2 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Robert Koremans
CEO & Director2.9yrs€2.50mpas de données
Luigi Felice Corte
Group CFO & Executive Director2.8yrs€1.23mpas de données
Cathrin Petty
Executive Director5.9yrspas de donnéespas de données
Giampiero Mazza
Executive Director5.9yrspas de donnéespas de données
Giorgio De Palma
Executive Director4.6yrspas de donnéespas de données
Andrea Recordati
Non-Executive Chairman26.6yrs€315.00kpas de données
Piergiorgio Peluso
Independent Non-Executive Director4.6yrs€80.00kpas de données
Michaela Castelli
Lead Independent Director10.6yrs€103.00kpas de données
Elisa Corghi
Independent Director2.8yrs€90.00kpas de données
Antonio Santi
Chairman of Statutory Auditor Board7.6yrspas de donnéespas de données
Joanna Le Couilliard
Independent Non-Executive Director5.8yrs€85.00kpas de données
Guido Guidi
Non-Executive Vice Chairman4.6yrs€90.00kpas de données

5.2yrs

Durée moyenne de l'emploi

54.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de REC sont considérés comme expérimentés (ancienneté moyenne 5.2 ans).